ACS Medicinal Chemistry Letters

Letter

Subscriber access provided by The Libraries of the | University of North Dakota

Selective PPAR# Modulators Improve Mitochondrial Function: Potential Treatment for Duchenne Muscular Dystrophy (DMD)

Bharat Lagu, Arthur F Kluge, Effie Tozzo, Ross Fredenburg, Eric L. Bell, Matthew M Goddeeris, Peter Dwyer, Andrew Basinski, Ramesh S Senaiar, Mahaboobi Jaleel, Nirbhay Kumar Tiwari, Sunil K Panigrahi, Narasimha Rao Krishnamurthy, Taisuke Takahashi, and Michael A Patane

ACS Med. Chem. Lett., Just Accepted Manuscript • DOI: 10.1021/acsmedchemlett.8b00287 • Publication Date (Web): 31 Jul 2018 Downloaded from http://pubs.acs.org on August 1, 2018

Just Accepted

"Just Accepted" manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides "Just Accepted" as a service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. "Just Accepted" manuscripts appear in full in PDF format accompanied by an HTML abstract. "Just Accepted" manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are citable by the Digital Object Identifier (DOI®). "Just Accepted" is an optional service offered to authors. Therefore, the "Just Accepted" Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the "Just Accepted" Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these "Just Accepted" manuscripts.



is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036

Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.

Selective PPARδ Modulators Improve Mitochondrial Function: Potential Treatment for Duchenne Muscular Dystrophy (DMD)

Bharat Lagu,^{*§} Arthur F. Kluge,[§] Effie Tozzo,[§] Ross Fredenburg,[§] Eric L. Bell,[§] Matthew M. Goddeeris,[§] Peter Dwyer,[§] Andrew Basinski,[§] Ramesh S. Senaiar,[≠] Mahaboobi Jaleel,[≠] Nirbhay Kumar Tiwari,[≠] Sunil K. Panigrahi,[≠] Narasimha Rao Krishnamurthy,[≠] Taisuke Takahashi,[¶] Michael A. Patane[§]

[§]Mitobridge, Inc. (a wholly owned subsidiary of Astellas Pharma.), 1030 Massachusetts Avenue, Cambridge MA 02138. [≠]Aurigene Discovery Technologies, Ltd., Bengaluru and Hyderabad, India.

[¶]Astellas Pharma., Tsukuba, Japan.

KEYWORDS PPARS modulators, Duchenne Muscular Dystrophy (DMD), mdx mouse, imidazoles, cis-amide

ABSTRACT: The x-ray structure of the previously reported PPARδ modulator **1** bound to the ligand binding domain (LBD) revealed that the amide moiety in **1** exists in the thermodynamically disfavored *cis*-amide orientation. Isosteric replacement of the *cis*-amide with five-membered heterocycles led to the identification of imidazole **17** (MA-0204), a potent, selective PPARδ modulator with good pharmacokinetic properties. MA-0204 was tested *in vivo* in mice and *in vitro* in patient-derived muscle myoblasts (from Duchenne Muscular Dystrophy (DMD) patients); **17** altered the expression of PPARδ target genes and improved fatty acid oxidation, which supports the therapeutic hypothesis for the study of MA-0204 in DMD patients.

DMD is an X-linked recessive genetic disease involving severe muscle wasting that results from cycles of muscle degeneration/regeneration.^{1,2} DMD patients carry mutations in the DMD gene, which encodes for dystrophin, a cellular protein scaffold that is critical for muscle membrane integrity.³ In addition to weakened structural integrity, DMD is also characterized by mitochondrial impairment with evidence of decreased fatty acid oxidative phosphorylation.⁴⁻⁷

In skeletal muscle, PPAR δ elicits a transcriptional cascade resulting in increased fatty acid oxidation while sparing glucose utilization, which enables muscle to function for a longer duration without decreasing systemic glucose levels or increasing muscle lactic acid.⁸ We hypothesized that engaging the PPAR δ transcriptional cascade with a selective PPAR δ modulator would provide functional improvements to DMD muscle.

The selectivity for PPAR δ is considered to be crucial to mitigate the undesirable effects (such as hepatotoxicity, myopathy, edema, cardiac toxicity etc.) observed with some modulators of PPAR α (fibrates),PPAR γ (thiazolidinediones) and the dual PPAR α/γ (e.g. Muraglitazar) in clinical and/or pre-clinical studies.^{9,10} While GW501516,¹¹ a known PPAR δ modulator, has shown tumorogenic effects in mice.¹² As per the company websites, two modulators of PPAR δ , Seladelpar and Elafibranor, have cleared the two-year carcinogenicity studies in rats. This suggests that tumorogenic potential is not a class effect for the PPAR modulators.

We recently disclosed the potent and selective PPARδ modulator **1** (**Figure 1**), which displayed significantly improved pharmacokinetic properties relative to previously reported compounds.¹³⁻ ¹⁵ The x-ray structure of **1** bound to the ligand binding domain (LBD) of the PPAR δ receptor revealed that the carbonyl oxygen and the N-methyl group is in a *cis* relationship.¹³ A *trans*-amide has been reported to be thermodynamically favored over a *cis*amide.¹⁶ *Cis*-amides are uncommon even in the peptide literature, especially for amino acids other than proline.¹⁷ Molecular mechanics-based energy minimization and conformational analysis of **1** predicted that the *trans* isomer is favored by 1.3 kcal/mol over the *cis* isomer.¹⁸ Therefore, we reasoned that a molecule in a "locked *cis*-amide" conformation would improve binding affinity for PPAR δ . Herein, we disclose a series of compounds represented by general structure **2**, wherein 5-membered heterocyclic rings (**Figure 1**) serve as isosteric replacements of the *cis*-amide bond.





The heterocyclic cores required for compounds **2a-g** were synthesized using known synthetic procedures (see supporting information for the detailed procedures). Synthesis of **2g** is shown in **Scheme 1** as a representative example.

PPARδ, PPARα and PPARγ activities of these compounds were assessed using transactivation assays.¹⁹ All the compounds were screened for exposure in mice following an intravenous dose of 3 mg/kg. The results are shown in **Table 1**.

 Table 1. Structure-activity relationship in the 5-membered heterocyclic series



Cpd	PPARδ EC ₅₀ nM ^a	PPARα EC ₅₀ nM ^{a,b}	t ½ (h) ^c	CL (mL/min/kg) ^c	AUC (ng*h/mL) ^c	
1	37±5	6,100	2.3	15	3300	
2a	1.5	5,840	0.2	180	280	
2b	9.5±0.5	7,250	0.8	55	900	
2c	1.3±0.5	412±7.1	0.8	300	170	
2d	1.2	13,100	0.4	130	380	
2e	8.4 ±1.4	16,800	0.2	225	220	
2f	59±3.6	ND	0.7	720	70	
2g	1.0±0.0	1,230 ±165	0.5	160	300	

^{*a*}Transactivation assay¹⁵ In selected cases, compounds were also assayed in a protein interaction assay.²⁰ Both assays were in good agreement. EC₅₀ values are an average of at least two experiments (SEM shown unless single determination); ^{*b*}All the compounds, except **2d**, showed EC₅₀ >10,000 nM for PPAR γ ; PPAR γ EC₅₀ for **2d** = 5530 nM; ^{*c*}Exposure data for compounds dosed i.v. at 3 mg/kg to CD-1 mice; ND = Not Determined.

Scheme 1. Synthesis of compound 2g.



Reagents and conditions: a) Prop-2-yn-1-amine, EDCI.HCl, HOBt, Et₃N, DMF, RT; b) (2-methoxyphenyl)methanamine,

Zn(OTf)₂, toluene, MW (irradiation), 140°C; c) BBr₃, DCM, RT; d) Furan-2-boronic acid, Pd(PPh₃)₄, Na₂CO₃, DME, EtOH, H₂O, 90°C; e) Methyl (*E*)-6-bromo-4-methylhex-4-enoate, K₂CO₃, DMF, 65°C; f) LiOH.H₂O, THF, EtOH, H₂O, RT

All of the heterocyclic compounds (except compound 2f) in Table 1 show greater affinity (EC₅₀ <10 nM) for PPAR δ receptor than the original amide lead 1, supporting our hypothesis regarding the use of heterocycles as *cis*-amide isosteres. All the compounds were found to selectively activate PPARδ (>1,000-fold less potent for PPAR α and PPAR γ receptors). Unlike compound 1, all the compounds (except 2b) shown in Table 1 have plasma clearances that exceeds hepatic blood flow in mice (>85 mL/min/kg), short half-lives (<1 h) and low plasma exposures (AUC <1,000 ng.h/mL) when dosed intravenously in mice. Compound 2b has the highest plasma exposure among the compounds shown in Table 1 but is 5-10-fold less potent for PPARS compared to the remaining compounds. Although 2d and 2g showed comparable PPAR δ activity and plasma clearance values, imidazole 2g was selected for further optimization based on the superior solubility properties (data not shown). Our previous work in the benzamide series (like compound 1) demonstrated that modifications of the hexenoic acid side chain significantly influence the observed pharmacokinetic (PK) properties.^{13,14} Therefore, similar chemistry exploration was undertaken in the imidazole series (e.g., 2g). Compounds 13 - 21 were synthesized as shown in Scheme 2. The results of pharmacological and pharmacokinetic studies are summarized in Table 2.

Scheme 2. General synthesis of compounds 13-21



Reagents and conditions: a) Prop-2-yn-1-amine, EDCI.HCl, HOBt, Et₃N, DMF, RT; b) (2-methoxyphenyl)methanamine, Zn(OTf)₂, toluene, microwave irradiation, 140°C; c) BBr₃, DCM, RT; d) For compounds **13-15**: Furan-2-boronic acid, Pd(PPh₃)₄, Na₂CO₃, DME, EtOH, H₂O, 90°C; e) R-Br (**11a** or **11b** or **11c**), K₂CO₃, DMF, 65°C; f) LiOH.H₂O, THF, EtOH, H₂O, RT

Table 2 (please see at the end of the manuscript)

In general, PPAR δ activity was significantly better for imidazole series of compounds (e.g. PPAR δ EC₅₀ = 37 nM for 1 compared to PPAR δ EC₅₀ = 1 nM for 2g). On the other hand, higher plasma exposures were observed for the compounds in the benzamide series compared to the imidazole series (e.g. AUC = 3300 ng*h/mL for 1 compared to 300 ng*h/mL for 2g). A significant improvement in plasma clearance and plasma exposures was observed when the hexanoic acid region included substitutions at α , 1

2

3

4

5

6

7

20

21

22

23

24

25

26

27

28

29

30 31

32

33 34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55 56

57 58 59

60

 β and γ positions relative to the carboxylic acid (e.g. 2g, 14 and 15 compared to 13). A similar trend in the pharmacokinetic properties was observed for the benzamide series of compounds.

Among the substituents tried as a replacement of the 2-furyl moiety (compounds 17-22), 4-trifluromethoxy group containing compound 17, stood out based on sub-nanomolar activity for PPAR δ , good selectivity over the other PPAR subtypes, reduced plasma clearance and improved plasma exposure.



Figure 2. Superposition of the x-ray structures of compound 1 (magenta) and compound 13 (cyan) bound to the ligand binding domain (LBD) of PPAR δ receptor

The x-ray structure of compound 13 bound to the LBD of PPAR δ (Figure 2) was obtained at 2Å resolution.²¹ As anticipated, the imidazole ring in 13 superimposes nicely with the *cis*-amide bond in the protein bound x-ray structure of 1. Almost all the interactions observed between 1 and the protein (His287, His413, Thr253 and Tyr437) are conserved in the x-ray structure for 13. One of the nitrogen atoms in the imidazole ring of 13 forms a water mediated interaction with Leu304 as was observed for the *cis*-amide in the x-ray structure for 1.¹³

The binding interactions with Val312 and Ile328 have been postulated to impart selectivity for a known PPAR δ selective modulator, GW0742.²² Overlay of the crystal structures of **13** with GW0742 (PDB ID: 3TKM) reveals a significant downward movement of the Ile328 residue in the structure for **13**, even though the Val312 conformation is conserved in both structures. This movement is possibly necessitated by the presence of the benzyl moiety on the imidazole ring. Ile328 in PPAR δ is replaced by methionine residues in PPAR α and PPAR γ . Changes in the Ile328 region and the water-mediated interaction with Leu304 potentially contribute to the improved PPAR δ selectivity for the imidazole series of compounds.

Compound 17 was profiled in multiple in vitro and in vivo assays (Table 3). Compound 17 is >10,000-fold selective for activation of PPAR δ over PPAR α and PPAR γ receptors. The PPAR δ potency was 10-fold less for mouse and rat PPAR8 receptors than for the human PPAR δ receptor; this affect is well documented for PPAR modulators.¹¹ Compound 17 is selective (EC₅₀ >10 μ M) over other nuclear receptors, for example: androgen, progesterone and glucocorticoid receptors. Compound 17 is also inactive in a panel of 68 receptors and transporters that are known to pose safety-related challenges in the clinic. Compound 17 exhibits high protein binding to mouse plasma, good permeability and low potential for efflux. Compound 17 did not show mutagenic potential or inhibit major cytochrome P450 enzymes (IC₅₀ \geq 10 μ M). Compound 17 has acceptable PK profiles in mice and rats upon oral dosing.²³ In the aggregate, these properties made 17 (MA-0204) an excellent candidate for study in pharmacological assays.

Table 3. Pote	ncy, selectivity,	ADME,	DMPK,	PK	and	Safety
data for 17 (M	IA-0204)					

Assay	Results					
Human PPARδ	$EC_{50} = 0.4 \text{ nM}^{a}$					
Human PPAR α and PPAR γ	$EC_{50} = 6,990\pm1,030$ nM and >100,000 nM respectively ^a					
Mouse PPARδ and Rat PPARδ	$EC_{50} = 7.9 \text{ nM} \text{ and } 10 \text{ nM}^{b}$					
Selectivity	No activity in Eurofins PanLabs Lead Profiling Screen [®] of 68 molecular targets up to 10µM. No activity (up to 10µM) for androgen, progesterone and gluco- corticoid recentors [°]					
%Plasma Protein Binding:	Mouse/Rat/Human = 99.5/99.6/99.9					
Caco-2 permeability (cm/sec, E-06)	A to $B = 36$; B to $A = 41$ (Efflux ratio 1.2)					
CYP450 inhibition	>10 μ M for CYPs except 2C9 (56% inhibition (a) 10 μ M)					
Mutagenicity	Non-mutagenic in mini-Ames test					
Mouse PK ^d	1 mg/kg IV: t ¹ / ₂ = 2.7 h; CL = 33 mL/min/kg; Vss = 5.8 L/kg ; AUC = 503 ng*h/mL 3 mg/kg PO: t ¹ / ₂ = 3.4 h; Cmax = 510 ng/mL; AUC = 630 ng*h/mL; %F = 42					
Rat PK ^e	1 mg/kg $\overline{IV: t'_{2} = 6.1 h}$; Vss = 1.8 L/kg ;CL = 10 mL/min/kg; AUC = 1,590 ng*h/mL 3 mg/kg PO: $t'_{2} = 4.6 h$; Cmax = 1,089 ng/mL; AUC = 4,920 ng*h/mL; %F = 90					
Monkey PK ^f	3 mg/kg IV: t ¹ / ₂ = 6.1 h; CL = 0.4 mL/min/kg; Vss = 3.2 L/kg ; AUC = 8,400 ng*h/mL 10 mg/kg PO: t ¹ / ₂ = 7.3 h: Cmax = 1,660 ng/mL; AUC = 3,840 ng*h/mL; %F = 13					

^aTransactivation assay; ^bData from Indigo Bioscience assay; ^cData obtained at Aurigene Discovery Technologies Pvt. Ltd.; ^dMale CD-1 mice (n = 3); ^eMale Wistar rats (n = 3); ^fMale cynomolgus monkeys (n = 3)

For compound 17 (MA-0204) to be considered as a potential treatment for Duchene Muscular Dystrophy (DMD), it was necessary to demonstrate that it met at least three criteria: (1) elicit a response in the target tissue, i.e., skeletal muscle, (2) affect changes in the PPARô-responsive genes in DMD patient myoblasts and (3) affect beta oxidation of fatty acid in patient myoblasts. The results from theses *in vivo* and *ex-vivo* experiments are described below.

To determine if **17** was capable of eliciting a biological effect in skeletal muscle, mice were dosed orally with MA-0204 and GW501516 and target gene expression was assessed by qPCR (quantitative polymerase chain reaction). As shown in **Figure 4**, **17** increased PPAR δ target gene transcription in the muscle, represented here by *Pdk4* (pyruvate dehydrogenase kinase 4).



Figure 4. Compound **17** (MA-0204) engages target gene expression after oral administration in mice (please see supporting information for details).

In order to test for changes in fatty acid oxidation, primary myoblasts isolated from a seventeen month old DMD patient were utilized. **17** increased PPAR δ target genes *ANGPTL4* (angiopoietin like protein 4), *CPT1a* (carnitine palmytoyltransferase 1a), and *PDK4* in a dose-dependent manner (**Figure 5**). Furthermore, oxidation of the long-chain fatty acid palmitic acid was significantly elevated at the concentrations of 1.2 nM, 4 nM and 12 nM (3-, 10-, and 30-fold EC₅₀, respectively), which represents a functional improvement of up to 52% in palmitate utilization (**Figure 6**).



Figure 5. Compound **17** (MA-0204) engages target gene expression in DMD patient muscle myoblasts. mice (please see supporting information for details).



Figure 6. Compound **17** (MA-0204) improves fatty acid oxidation in DMD patient muscle myoblasts mice (please see supporting information for details).

In summary, we have reported the design and synthesis of a series of potent and selective PPAR δ modulators by utilizing x-ray crystallographic information derived from previously disclosed compounds. The key compound to emerge from these studies, **17** (MA-0204), combined potency and PK properties which enabled the demonstration that selective the PPAR δ modulators may offer benefits as a therapeutic strategy for DMD.

ASSOCIATED CONTENT

Supporting Information

Supporting Information [experimental procedures, HPLC and ¹H NMRs, x-ray crystallographic data as a PDF] is available free of charge on the ACS Publications website at DOI: XXX.

AUTHOR INFORMATION

Corresponding Author

* Tel. 1(617)401-9122. E-mail: Bharat.lagu@astellas.com

Author Contributions

The manuscript was written through contributions of all authors. / All authors have given approval to the final version of the manuscript.

Notes

The authors are current or former employees of Mitobridge, Inc., Astellas Pharma. or Aurigene Discovery Technologies and may have or currently own shares of these companies.

ACKNOWLEDGMENT

Authors thank B. Mallesh (Aurigene Discovery Technologies) for technical assistance.

ABBREVIATIONS

DMSO, Dimethyl Sulfoxide; BBr₃, boron tribromide; DCM, dichloromethane; RT, room temperature; h, hour; Pd(PPh₃)₄, Tetrakis(triphenylphosphine)palladium(0); Na₂CO₃, sodium carbonate; DME, 1,2-dimethoxyethane; EtOH, ethyl alcohol; Li-OH.H₂O, lithium hydroxide monohydrate; THF, tetrahydrofuran; EDCI.HCl, ethylcarbodiimide hydrochloride; HOBt, 1-hydroxy benzotriazole; Et₃N, triethylamine; DMF, N,N-dimethyl formamide; Zn(OTf)₂, zinc trifluoromethanesulfonate.

REFERENCES

- Bushby, K., Finkel, R.; Birnkrant, D. J.; Case, L. E.; Clemens, P. R.; Cripe, L.; Kaul, A.; Kinnett, K.; McDonald, C.; Pandya, S.; Poysky, J.; Shapiro, F.; Tomezsko, J.; Constantin, C. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. *Lancet Neurol.*, 2010. 9(1): p. 77-93.
- Chelly, J.; Kaplan, J. C.; Maire, P.; Gauton, S.; Kahn, A. Transcription of the dystrophin gene in human muscle and non-muscle tissues. *Nature*, 1988, 333, 858.
- Ryder, S.; Leadley, R. M.; Armstrong, N.; Westwood, M.; de Kock, S.; Butt, T.; Jain, M.; Kleijnen, J.The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: an evidence review. Orphanet J Rare Dis., 2017. 12(1), 79.
- 4. Timpani, C. A., Hayes, A.; Rybalka, E. Revisiting the dystrophin-ATP connection: How half a century of research still implicates mitochondrial dysfunction in Duchenne Muscular Dystrophy aetiology. Med Hypotheses, **2015**, *85(6)*, 1021-33.
- Carroll, J. E., Norris, B. J.; Brooke, M. H. Defective [U-14 C] palmitic acid oxidation in Duchenne muscular dystrophy. *Neurology*, **1985**. *35(1)*, 96-7.
- Khairallah, M., Khairallah, R.; Young, M. E.; Dyck, J. R.; Petrof, B. J.; Des Rosiers, C., Metabolic and signaling alterations in dystrophin-deficient hearts precede

1

2

overt cardiomyopathy. J Mol Cell Cardiol. 2007. 43(2), 119-29.

- Lin, C. H., Hudson, A. J.; Strickland, K. P. Fatty acid oxidation by skeletal muscle mitochondria in Duchenne muscular dystrophy. *Life Sci II*, **1972**. *11(7)*, 355-62.
- Fan, W., Waizenegger W.; Lin, C. S.; Sorrentino, V.; He, M. X.; Wall, C. E.; Li, H.; Liddle, C.; Yu, R. T.; Atkins, A. R.; Auwerx, J.; Downes, M.; Evans, R. M. PPARdelta Promotes Running Endurance by Preserving Glucose. *Cell Metab*, **2017**, *25(5)*, 1186-1193 e4.
- Peraza, M. A.; Burdick, A. D.; Marin, H. E.; Gonzalez, F. J.; Peters, J. M. The Toxicology of Ligands for Peroxisome Proliferator-Activated Receptors (PPAR). *Tox. Sci.* 2006, 90, 269.
- Niessen, S. E.; Wolski, K.; Topol, E. J. Effect of Muraglitazar on death and major adversecardiovascular events in patients with type-2 diabetes mellitus *JAMA* 2005, 294(20), 2581.
- Sznaidman, M. L.; Haffner, C. D.; Malloney, P. R.; Fivush, A.; Chao, E.; Goreham, D.; Sierra, M. L.; LeGrummelec, C.; Xu, E. H.; Montana, V. G.; Lambert, M. H.; Willson, T. M.; Oliver, W. R.; Sternbach, D. D. Novel selective small molecule agonists for peroxisome proliferator-activated receptor delta (PPARdelta)synthesis and biological activity. *Bioorg. Med. Chem. Lett.* 2003, *13*, 1517.
- Geiger, L. E.; Dunsford, W. S.; Lewis, D. J.; Brennan, C.; Liu, K. C.; Newsholme, S. J. Rat carcinogenicity study with GW501516, a PPAR delta agonist. 48th Annual Meeting of the Society of Toxicology, 2009, PS-895.
- Lagu, B.; Kluge, A. F.; Fredenburg, R. A.; Tozzo, E.; Senaiar, R. S.; Jaleel, M.; Panigrahi, S. K.; Tiwari, N. K.; Krishnamurthi, N. R.; Takahashi, T.; Patane, M. A. Novel highly selective peroxisome proliferatoractivated receptor delta (PPARδ) modulators with pharmacokinetic properties suitable for once-daily oral dosing. *Bioorg Med Chem Lett.*, **2017**, *27(23)*: 5230-5234.
- Lagu, B., Kluge, A. F.; Goddeeris, M. M.; Tozzo, E.; Fredenburg, R. A.; Chellur, S.; Senaiar, R. S.; Jaleel, M.; Krishna Babu, R. D.; Tiwari, N. K.; Krishnamurthi, N. R.; Takahashi, T.; Patane, M. A. Highly selective peroxisome proliferator-activated receptor delta (PPAR)

modulator demonstrates improved safety profile compared to GW501516. *Bioorg Med Chem Lett*, **2018**, *28*, 533.

- Wu, C. C.; Baiga, T. J.; Downes, M.; La Clair, J. J.; Atkins, A. R.; Richard, S. B.; Fan, W.; Stockley-Noel, T. A.; Bowman, M. E.; Noel, J. P.; Evans, R. M. Structural basis for specific ligation of the peroxisome proliferator-activated receptor δ *Proc. Natl. Acad. Sci.* 2017, *114*, E2563.
- Jorgensen, W. L.; Gao, J. Cis-trans energy difference for the peptide bond in the gas phase and in aqueous solution. J. Am. Chem. Soc. 1988. 110 (13), 4212-4216.
- 17. Weiss, M. A.; Jabs, A.; Hilgenfeld, R. H. "Peptide bond revisited" *Nat. Str. Biol.* **1998**, *5*(8), 676.
- Molecular mechanics based energy minimization and conformational analysis study using Molsoft/MMFF force field.
- 19. In the transactivation assay CV-1 cells are transfected with a PPAR ligand binding domain fused to a GAL4 promoter to generate a hormone-inducible activator. A test ligand is added and activity is measured in a luciferase assay. See WO2016057660 for further details.
- 20. In the protein interaction assay the PPAR ligand complexes with a PPAR ligand binding domain fused to an inactive fragment of galactosidase. This complex complements another inactive galactosidase fragment to form an active galactosidase enzyme that is read out in a fluorescence assay. See www.discoverx.com for details.
- 21. Coordinates of the X-ray structure have been deposited in the Protein Data Bank (accession code PDB 5ZXI).
- Batista, F. A. H.; Trivella, D. B. B.; Bernardes, A.; Gratieri, J.; Oliveira, P. S. L.; Figueira, A. C. M.; Webb, P.; Polikarpov, I. Structural insights into human peroxisome proliferator activated receptor delta (PPAR-delta) selective ligand binding. *PLos One* 2012, *7*, e33643.
- 23. All the animal experiments were carried out as per the guidelines of the Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA), Government of India and approved by the Institutional Animal Ethics Committee (IAEC), Aurigene Discovery Technologies Ltd, Bengaluru, India.

Table 2. Hexanoic acid region modifications, PPAR activity and selected pharmacokinetic data



Cpd	R ₁	Hexanoic acid region Modifications	PPARδ EC ₅₀ (nM) ^a	PPARa EC ₅₀ (nM) ^a	t½ (h) ^b	CL (mL/min/kg) ^b	AUC (ng*h/mL) ^b
1			37±5	6,100	2.3	15	3300
2g	4-(2-furyl)	А	1.0±0.0	1,230±165	0.5	160	300

13	4-(2-furyl)	В	0.7±0.2	6,970	0.3	270	180
14	4-(2-furyl)	С	4.5	ND	2.4	120	400
15	4-(2-furyl)	D	3.7±0.1	>100,000	1.4	73	650
16	OCF ₃	А	0.3±0.1	2,290	3.1	70	240°
17	4-OCF ₃	D	0.4±0.1	6,900 ±1030	3.3	25	1250
18	4-Cl-3-F	D	0.8±0.1	69,000	4.3 ^c	38 ^c	440 ^c
19	4-Cl	D	5.5±2.8	>100,000	1.4 ^c	22 ^c	752 ^c
20	4-Me	D	20±4.8	78,500	ND	ND	ND
21	4-OCHF ₂	D	13.5	15,060	ND	ND	ND
22	4-F	D	39.0	>100,000	ND	ND	ND

^{*a*}Transactivation assay¹⁵ In selected cases, compounds were also assayed in a protein interaction assay.¹⁶ Both assays were in good agreement. EC_{50} values are an average of at least two experiments (SEM shown unless single determination); ^{*b*}Exposure data for compounds dosed i.v. at 3 mg/kg to CD-1 mice; ^{*c*}Exposure data for compounds dosed i.v. at 1 mg/kg to CD-1 mice; ND = Not Determined. All the compounds showed $EC_{50} > 10,000$ nM for PPAR γ .



Selective PPARδ Modulators Improve Mitochondrial Function: Potential Treatment for Duchenne Muscular Dystrophy (DMD)

Bharat Lagu,^{*§} Arthur F. Kluge,[§] Effie Tozzo,[§] Ross Fredenburg,[§] Eric L. Bell,[§] Matthew M. Goddeeris,[§] Peter Dwyer,[§] Andrew Basinski,[§] Ramesh S. Senaiar,[≠] Mahaboobi Jaleel, [≠] Nirbhay Kumar Tiwari, [≠] Sunil K. Panigrahi,[≠] Narasimha Rao Krishnamurthy,[≠] Taisuke Takahashi,[¶] Michael A. Patane[§]

[§]Mitobridge, Inc. (a wholly owned subsidiary of Astellas Pharma.), 1030 Massachusetts Avenue, Cambridge MA 02138.

^{*±*}Aurigene Discovery Technologies, Ltd., Bengaluru and Hyderabad, India.

[¶]Astellas Pharma., Tsukuba, Japan.

Graphical Abstract

